Abstract 403P
Background
The use of ALK inhibitors is one of the success stories in the precision medicine for treating advanced ALK-positive non-small cell lung cancer (NSCLC). However, the developing countries have significant cost constraints in using ALK inhibitors. The primary objective of this study was to investigate the treatment patterns and outcomes in Indian ALK-positive NSCLC patients.
Methods
An audit of a prospectively collected database of advanced ALK-positive NSCLC patients treated from Jan 2013 to Dec 2017 was conducted. Patients were divided into those who received ALK inhibitor in first-line (including upfront strategy, or after a few chemotherapy cycles), or who did not receive ALK inhibitor in the first line. SPSS version 20.0 was used for statistical analysis.
Results
A total of 461 patients were available for analysis, 62.5% were males, median age 50 years (range 19-75) and 78.3% had ECOG PS 0-1. 169 (36.7%) patients were started on crizotinib upfront, 232 (50.3%) on chemotherapy, 12 (2.6%) received second/third-generation ALK inhibitors, and 22 (4.8%) patients were offered best supportive care. The main reasons for not starting crizotinib upfront included patients not willing to wait for the report (49.6%), financial constraints (21.3%), and symptomatic patients needing early initiation of therapy (13.3%). 78 (16.9%) patients were shifted to crizotinib after 1-2 cycles and 38 (8.2%) after 4-6 cycles of chemotherapy. The median progression-free survival on first-line therapy for the entire cohort was 14.1 months (m) (95% CI: 12.2-15.9), with a significant difference between patients receiving ALK inhibitor in first-line in any strategy vs. not in first-line [17.8 m (95% CI:14.9-20.8) vs. 5.9 m (95% CI:4.2-7.7), p<0.001). The median overall survival was 29.8 m (95% CI: 24.8-34.8), with 37.7 m (95% CI: 28.5-46.9) for ALK inhibitor in first-line vs. 20.2 m (95% CI: 15.6-24.7) for not in first-line (p<0.001). 295 (63.1%) received crizotinib completely free via various extramural support schemes.
Conclusions
A majority of our ALK-positive NSCLC patients were exposed to crizotinib through various support mechanisms. Those patients who could receive ALK inhibitors in the first-line had a significant survival advantage.
Clinical trial identification
CTRI/2013/01/003335.
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session